Genomic Profiling for Bladder Cancer
Decipher Bladder is the only genomic subtyping tool available to physicians in the United States treating patients with locally advanced bladder cancer.
in classifying bladder tumors into four molecular subtypes
genome-wide assay of 46,000 genes
model derived from the Cancer Genome Atlas project
Decipher Bladder accurately classifies the molecular subtype of AJCC Stage I to IIIA bladder cancer tumors to provide physicians and patients with more information to make treatment decisions.
Indicated for patients with AJCC Stage I to IIIA bladder cancer
Uses a whole transcriptome microarray to measure 219 genes
Provides the tumor molecular subtype:
Badrinath Konety, MD
University of Minnesota
“Decipher Bladder can reveal the biological nature of the patient’s tumor. It is the most promising tool we currently have available as a potential aid in clinical decision making prior to radical cystectomy.”
Physicians \ Order a Test
2. Fax the completed form, along with the pathology report and insurance information to:
Specimen Acceptance Criteria
ALL Gleason Scores
ALL PSA Values
ALL Gleason Scores
ALL PSA Values (including undetectable, rising, and persistently elevated PSA)
of Bladder Tumor) from AJCC Stage I to IIIA bladder cancer
Patients \ Insurance Information
Veracyte is committed to ensuring access to Decipher genomic testing for all patients.
Decipher Prostate is covered by Medicare, Medicare Advantage and select private insurers.
Through Decipher Assist, we offer programs designed to ensure testing is affordable for patients, including:
• Financial assistance for patients with demonstrated financial need
• Tailored payment plans to accommodate certain specific financial circumstances
Veracyte’s Decipher Bladder is covered by Medicare for patients with AJCC Stage I to IIIA bladder cancer. For more information, please contact the Decipher billing team at: 1.888.792.1601 and select option #3.